US senators accuse Novartis execs of greed for hiding manipulated Zolgensma data — and the next step could affect the industry
The second act in Novartis’ Zolgensma drama opened on Friday.
A group of US senators issued their own furious slapdown for the company’s decision to keep information about manipulated data on Zolgensma hidden from the FDA during the review process. And this attack includes a shot right over the industry’s bow — with potential consequences for all drug developers.
The letter — signed by a group that includes two Democratic candidates for president, Bernie Sanders and Elizabeth Warren — accused Novartis of greed as well as an outrageous refusal to express remorse in its statement regarding the incident involving Zolgensma.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.